A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

British Journal of Cancer

Volumn 97, Issue 4, 2007, Pages 458-463

  Jeung, H C ^a   Rha, S Y ^a,b   Shin, S J ^a,b   Ahn, J B ^a,b   Noh, S H ^a,b   Roh, J K ^a,b   Chung, H C ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Gastric adenocarcinoma; Performance status; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPIRATION PNEUMONIA; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; STOMACH CANCER; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547856610     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603902     Document Type: Article

References (25)

1. Andreyev HJN, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34: 503-509
2. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 15: 64-69
3. Beretta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Mariani L, Gevorgyan A, Bajetta E (2006) Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. Tumori 92: 379-383
4. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G (1998) Phase II study of paclitaxel in pre-treated advanced gastric cancer. Anticancer Drugs 9: 307-310
5. Chao Y, Teng HC, Hung HC, King KL, Li CP, Chi KH, Yen SH, Chang FY 2000) Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. Jpn J Clin Oncol 30: 122-125
6. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM (2004) Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 23: 8-13
7. Cunningham D, Hole D, Taggart DJ, Soukop M, Carter DC, McArdle CS 1987) Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival. Br J Surg 74: 715-720
8. Horinaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9: 14-18
9. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Chen YC, Cheng AL (1997) Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancer: an effective and low-toxic regimen for patients with poor general condition. Oncology 54: 275-280
10. Janunger KG, Halfstrom L, Nygen P, Glimelius B (2001) A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 40: 309-326
11. Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB 2006) A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 95: 1637-1641
12. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC (2007) Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetics and pharmacogenomic evaluations. Oncologist 12: 543-554
13. Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, Tanigawa T, Yamamoto H, Kurokawa E (2003) A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 6: S34-S39
14. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197
15. Lavin PT, Bruckner HW, Plaxe SC (1982) Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 50: 2016-2023
16. Maehara Y, Sugimachi K, Ogawa M, Kakegawa T, Shimazu H, Tomita M (1993) Influence of preoperative performance status on survival time of patients with advanced gastric cancer following noncurative resection. Anticancer Res 13: 201-204
17. Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide postmarketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8: 6-11
18. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D, Cvitkovic E, Armand JP, Droz JP (1994) Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30A: 1263-1269
19. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drugs S-1 (1M tegafur-0.4M gimestat- 1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720
20. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57: 202 -210
21. Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M, Hickish T (2006) Efficacy and tolerability in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 42: 827-834
22. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, Kohne-Wompner CH, Harstrick A, Schmoll HJ (1990) New developments in the treatment of gastric carcinoma. Semin Oncol 17: S61-S70
23. Wilson D, Hiller L, Geh JI (2005) Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 17: 81-90
24. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS (2000) Recurrence following curative resection for gastric carcinoma. Br J Surg 87: 236-242
25. Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH (2007) Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advance upper gastrointestinal cancer. Cancer Chemother Pharmacol 59: 285-293